行业标准数据检索

Requirements for heptatitis B vaccine prepared from plasma , Annex 8

Recommendations to assure the quality, safety and efficacy of recombinant hepatitis B vaccines. proposed replacement of:L TRS 786, Annex 2 and TRS 889, Annex 4

TRS No.889

WHO/BS/06.2050

Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines

TRS No.927_A3

Recommendations for the production and control of influenza vaccine (inactivated), Annex 3

WHO/IMD/PUB/04.1

WHO recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration

TRS No.941_A5

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines, Annex 5

TRS No.941_A5

H1N1 specific-update of TRS 941, Annex 5

WHO/BS/07.2074

Proposed guidelines: regulatory preparedness for human pandemic influenza vaccines

WHO/BS/07.20644

Proposed revision recommendations for Japanese encephalitis vaccine (inactivated) for human use

TRS No.910_A3

Guidelines for the production and control of Japanese encephalitis vaccine (live) for human use , Annex 3

TRS No.840_A3

Requirements for measles, mumps and rubella vaccines and combined vaccine (live), Annex 3

WHO/BS/06.2041

Recommendations to assure the quality, safety and efficacy of group a meningococcal conjugate vaccines

TRS No.924_A2

Recommendations for the production and control of Meningococcal group C conjugate vaccines, Annex 2

TRS No.926_A2

Recommendations for the production and control of group C meningococcal conjugate vaccines, Addendum 2003, Annex 3

WHO/BS/07.2065

Clinical evaluation of group C meningococcal conjugate vaccines

TRS No 904_A2

Requirements for meningococcal polysaccharide vaccine (Amendment 1999), Annex 2

TRS No.658_A2

Requirements for meningococcal polysaccharide vaccine, Addendum 1980, Annex 6

TRS No.594_A2

Requirements for meningococcal polysaccharide vaccine: Adopted 1975, Annex 2

TRS No.848

NOTE: requirements for measles, mumps and rubella vaccines and combined vaccine (live)(requirements for biological substances NO.47)

TRS No.941_A6

Recommendations for whole cell pertussis vaccine, Annex 6

TRS No.800_A2

Requirements for diphtheria, tetanus, pertussis and combined Vaccines, Annex 2

TRS No.927_A5

Recommendations for diphtheria, tetanus, pertussis and combined Vaccines, Amendment 2003, Annex 5

TRS No.878_A2

Guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines, Annex 2

TRS No.927_A2

Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines-proposed replacement of TRS 927, Annex 2

TRS No.926_A2

Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufacturered from wild polioviruses (Addendum 2003 to recommendations for the production and quality control of poliomyelitis vaccine (Inactivated)), Annex 2

TRS No.910_A2

Recommendations for the production and control of poliomyelitis vaccine (Inactivated), Annex 2

TRS No.910_A2

Recommendations for the production and control of poliomyelitis vaccine (oral) (Addendum 2000), Annex 1

TRS No.904_A1

Recommendations for the production and control of poliomyelitis vaccine, oral; Revised 1999, Annex 1

TRS No.941_A2

Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs, Annex 2

TRS No.658_A2

Requirements for rabies vaccine for human use, Revised 1980, Annex 2

TRS No.673_A4

Requirements for rift valley fever vaccines; Adopted 1981, Annex 4

TRS No.941_A3

Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral), Annex 3

TRS No.840_A3

Requirements for measles, mumps and rubella vaccines and combined vaccines, live, Annex 3

TRS No.926_A1

Recommendations for the production and quality control of smallpox vaccines, Annex 1

TRS No.889_A1

Guidelines for the production and quality control of synthetic peptide vaccines; Adopted 1997, Annex 1

TRS No.880_A2

Requirements for diphteria, tetanus, pertussis and combined vaccines, Annex 2

TRS No.927_A5

Recommendations for diphtheria, tetanus, pertussis and combined vaccines, Amendments 2003, Annex 5

TRS No.889_A2

Requirements for tick-borne encephalitis vaccine (inactivated), Adopted 1997, Annex 2

TRS No.840_A1

Requirements for vi polysaccharide typhoid vaccine; Adopted 1992, Annex 1

TRS No.361_A4

Requirements for typhoid vaccine; Adopted 1966, Annex 4

TRS No.700_A3

Requirements for typhoid vaccine (Live, attenuated, Ty 21a, oral), Annex 3

TRS No.848_A1

Requirements for varicella vaccine (Live); Revised 1993, Annex 1

TRS No.872

Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines.

TRS No.786_A3

Requirements for human interferons from lymphoblastoid cells, Annex 3

TRS No.771_A7

Requirements for human interferons by recombinant DNA techniques, Annex 7

TRS No.924_A1

Guidelines on clinical evaluation of vaccines: regulatory expections, Annex 1

TRS No.822_A1

Biological products, GMP, Annex 1

TRS No.908

WHO expert committee on specifications for pharmaceutical preparations

TRS No.932

Guidelines for independent lot release of vaccines by regulatory authorities.

标准编号	标准名称	发布日期	实施日期	废止日期	替换信息
TRS No.771_A8	Requirements for heptatitis B vaccine prepared from plasma , Annex 8
TRS No.786	Recommendations to assure the quality, safety and efficacy of recombinant hepatitis B vaccines. proposed replacement of:L TRS 786, Annex 2 and TRS 889, Annex 4
TRS No.889
WHO/BS/06.2050	Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines
TRS No.927_A3	Recommendations for the production and control of influenza vaccine (inactivated), Annex 3
WHO/IMD/PUB/04.1	WHO recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration
TRS No.941_A5	WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines, Annex 5
TRS No.941_A5	H1N1 specific-update of TRS 941, Annex 5
WHO/BS/07.2074	Proposed guidelines: regulatory preparedness for human pandemic influenza vaccines
WHO/BS/07.20644	Proposed revision recommendations for Japanese encephalitis vaccine (inactivated) for human use
TRS No.910_A3	Guidelines for the production and control of Japanese encephalitis vaccine (live) for human use , Annex 3
TRS No.840_A3	Requirements for measles, mumps and rubella vaccines and combined vaccine (live), Annex 3
WHO/BS/06.2041	Recommendations to assure the quality, safety and efficacy of group a meningococcal conjugate vaccines
TRS No.924_A2	Recommendations for the production and control of Meningococcal group C conjugate vaccines, Annex 2
TRS No.926_A2	Recommendations for the production and control of group C meningococcal conjugate vaccines, Addendum 2003, Annex 3
WHO/BS/07.2065	Clinical evaluation of group C meningococcal conjugate vaccines
TRS No 904_A2	Requirements for meningococcal polysaccharide vaccine (Amendment 1999), Annex 2
TRS No.658_A2	Requirements for meningococcal polysaccharide vaccine, Addendum 1980, Annex 6
TRS No.594_A2	Requirements for meningococcal polysaccharide vaccine: Adopted 1975, Annex 2
TRS No.848	NOTE: requirements for measles, mumps and rubella vaccines and combined vaccine (live)(requirements for biological substances NO.47)
TRS No.941_A6	Recommendations for whole cell pertussis vaccine, Annex 6
TRS No.800_A2	Requirements for diphtheria, tetanus, pertussis and combined Vaccines, Annex 2
TRS No.927_A5	Recommendations for diphtheria, tetanus, pertussis and combined Vaccines, Amendment 2003, Annex 5
TRS No.878_A2	Guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines, Annex 2
TRS No.927_A2	Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines-proposed replacement of TRS 927, Annex 2
TRS No.926_A2	Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufacturered from wild polioviruses (Addendum 2003 to recommendations for the production and quality control of poliomyelitis vaccine (Inactivated)), Annex 2
TRS No.910_A2	Recommendations for the production and control of poliomyelitis vaccine (Inactivated), Annex 2
TRS No.910_A2	Recommendations for the production and control of poliomyelitis vaccine (oral) (Addendum 2000), Annex 1
TRS No.904_A1	Recommendations for the production and control of poliomyelitis vaccine, oral; Revised 1999, Annex 1
TRS No.941_A2	Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs, Annex 2
TRS No.658_A2	Requirements for rabies vaccine for human use, Revised 1980, Annex 2
TRS No.673_A4	Requirements for rift valley fever vaccines; Adopted 1981, Annex 4
TRS No.941_A3	Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral), Annex 3
TRS No.840_A3	Requirements for measles, mumps and rubella vaccines and combined vaccines, live, Annex 3
TRS No.926_A1	Recommendations for the production and quality control of smallpox vaccines, Annex 1
TRS No.889_A1	Guidelines for the production and quality control of synthetic peptide vaccines; Adopted 1997, Annex 1
TRS No.880_A2	Requirements for diphteria, tetanus, pertussis and combined vaccines, Annex 2
TRS No.927_A5	Recommendations for diphtheria, tetanus, pertussis and combined vaccines, Amendments 2003, Annex 5
TRS No.889_A2	Requirements for tick-borne encephalitis vaccine (inactivated), Adopted 1997, Annex 2
TRS No.840_A1	Requirements for vi polysaccharide typhoid vaccine; Adopted 1992, Annex 1
TRS No.361_A4	Requirements for typhoid vaccine; Adopted 1966, Annex 4
TRS No.700_A3	Requirements for typhoid vaccine (Live, attenuated, Ty 21a, oral), Annex 3
TRS No.848_A1	Requirements for varicella vaccine (Live); Revised 1993, Annex 1
TRS No.872	Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines.
TRS No.786_A3	Requirements for human interferons from lymphoblastoid cells, Annex 3
TRS No.771_A7	Requirements for human interferons by recombinant DNA techniques, Annex 7
TRS No.924_A1	Guidelines on clinical evaluation of vaccines: regulatory expections, Annex 1
TRS No.822_A1	Biological products, GMP, Annex 1
TRS No.908	WHO expert committee on specifications for pharmaceutical preparations
TRS No.932	Guidelines for independent lot release of vaccines by regulatory authorities.